FDA warning letters about compounded GLP-1 drugs were about marketing, not a ban. FDA said telehealth companies made false or misleading claims about compounded drugs, including GLP-1s like semaglutide, such as implying FDA approval or promising the same results as brand-name drugs. Compounded medications are not FDA-approved. This guide explains what the letters mean and gives you a checklist for reading any GLP-1 page.
Key takeaways
- FDA's warning letters targeted false or misleading website claims about compounded drugs, including GLP-1s, which federal law treats as misbranding.
- A warning letter is a formal notice that asks a company to fix violations, not a court order or a product ban.
- We group the claims FDA warns against into five kinds: implied FDA approval, "generic" or "same as" framing, "same results" claims, "FDA-approved" or "FDA-licensed" pharmacy claims, and branding that hides who makes the drug.
- No pharmacy or outsourcing facility is FDA-approved or FDA-licensed, and registering with FDA is not approval.
- A trustworthy GLP-1 page says plainly that the drug is compounded and not FDA-approved, who makes it, and that a licensed clinician decides whether it is appropriate.
Why FDA sent warning letters about compounded GLP-1 marketing
FDA sent the letters because it found that telehealth companies made false or misleading claims about compounded drugs, including GLP-1s, and that this violates federal law (FDA telehealth guidance, 2026). The letters were about how products were described. They did not rule on whether compounding is allowed at all.
Two definitions help. Compounding means a pharmacy mixes or alters drug ingredients to prepare a medication, instead of dispensing a finished product made under FDA approval. Misbranding is a legal term. Under section 502(a) of the Federal Food, Drug, and Cosmetic Act, a drug is misbranded if its labeling is false or misleading in any particular. Under section 502(bb), a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular (FDA warning letter, June 8, 2026).
FDA says it has issued warning letters to telehealth companies over false or misleading claims (FDA telehealth guidance, 2026). One example is a warning letter dated June 8, 2026, and posted on FDA.gov on June 16, 2026 (FDA warning letter, June 8, 2026). This guide uses that letter to show what FDA objects to in practice.
FDA didn't need to inspect a facility to find these problems. In the June 2026 letter, FDA's Office of Compounding Quality and Compliance said it found the violations by reviewing the company's website in March 2026 (FDA warning letter, June 8, 2026).
What safety concerns sit behind the enforcement?
FDA has received hundreds of adverse event reports for each of compounded semaglutide and compounded tirzepatide, and it says the real number is likely higher. An adverse event report is a report sent to FDA describing a health problem that happened after someone used a drug.
As of May 31, 2026, FDA had received 990 reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide (FDA concerns page, 2026). FDA says these are likely underreported, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events. FDA also notes that many reported events look like those seen with the FDA-approved versions. Some reports, including some that required hospitalization, may be related to dosing errors with compounded injectable semaglutide.
These numbers need context. Spontaneous reports show what people chose to send to FDA. They cannot prove a drug caused an event, and they don't show how often problems happen. FDA's page also warns about fraudulent compounded GLP-1 products (FDA concerns page, 2026), which is one more reason to know who actually makes your medication.
Misleading claims FDA warns about, grouped into five types
FDA has published a list of claims telehealth companies should not make about compounded drugs (FDA telehealth guidance, 2026). We group them into five categories. This article names no company, because the patterns matter more than the names.
| Claim type | What it can look like | Why FDA objects |
|---|---|---|
| 1. Implied FDA approval | Wording that makes a compounded product, which is not FDA-approved, sound approved or reviewed for safety and effectiveness | FDA does not review compounded drugs for safety, effectiveness or quality before they are sold |
| 2. "Generic" or "same as" | Calling the compounded drug a generic version of, or the same as, a brand-name drug | FDA approves generics before they are marketed, and it does not approve compounded drugs |
| 3. "Same results" | Saying the compounded drug is clinically proven to produce the same result as the approved drug | FDA has not reviewed the compounded product to show that |
| 4. "FDA-approved" or "FDA-licensed" pharmacy | Saying the drug comes from an FDA-approved or FDA-licensed pharmacy or facility | FDA does not approve or license any facility |
| 5. Telehealth brand posing as the compounder | Branding that implies the website company makes the drug | It misleads you about where the drug comes from |
The June 2026 letter shows how these claims look in practice. In paraphrase, FDA cited a site that described compounded semaglutide, which is not FDA-approved, as combining an FDA-approved active ingredient with a vitamin. FDA also cited a claim that compounded drugs give the same results as brand names for much less money. It flagged wording that tied the ingredient to FDA-approved products as well. FDA said these claims presented the products as FDA-approved or evaluated for safety and effectiveness when they were not (FDA warning letter, June 8, 2026).
The lesson for patients is simple. A claim can be technically about the ingredient and still mislead you about the product.
Do FDA warning letters mean compounded GLP-1s are illegal?
Not by themselves. A warning letter is a formal notice that FDA believes a company is violating the law and should correct it. It is not a court order, and it does not ban a drug.
The June 2026 letter gave the company 15 business days to respond. It warned that failing to address the violations could lead to legal action such as seizure or injunction (FDA warning letter, June 8, 2026). The corrective steps it suggested included identifying the entities that produce the compounded products offered on the website.
Marketing is only one part of the picture. The same letter reminds companies that compounded drugs must meet the conditions of section 503A or section 503B to be exempt from certain federal requirements, including new drug approval. So the status of a particular compounded product depends on how and where it is compounded, not only on how it is advertised.
FDA's own view is direct: compounded drugs should only be used for patients whose medical needs an FDA-approved drug is not able to meet (FDA concerns page, 2026). That is FDA's stated position, and it's worth knowing if you are weighing a compounded option.
Rules and enforcement can change. Check FDA.gov for current information, and ask your clinician how any change affects you.
A checklist: is this GLP-1 page implying equivalence?
You can run this check on any GLP-1 website in a few minutes. If a page trips several items, treat its claims with caution.
- Red-flag words: "generic", "same as", "equivalent", "identical", "same results", "clinically proven" applied to a compounded product (which is not FDA-approved), "FDA-approved pharmacy" or "FDA-licensed".
- Brand-name piggybacking: a brand name in the product title, or a comparison with a brand that implies you'll get the same outcome.
- Approval by association: calling the ingredient "FDA-approved" in a way that makes a compounded product, which is not FDA-approved, sound approved.
- Missing disclosure: no plain statement near the product that it is compounded and not FDA-approved.
- Hidden source: the product appears only under the telehealth brand, with no mention of a licensed pharmacy or outsourcing facility.
- Outcome promises: specific amounts of weight loss or timelines. FDA has not reviewed compounded products for effectiveness, so results from brand-name trials can't simply be borrowed.
This checklist covers marketing claims. To verify the pharmacy and product quality, use the compounded GLP-1 safety checklist.
Who actually makes a compounded GLP-1?
A pharmacy or outsourcing facility makes it, not the website. A telehealth company is usually a platform that connects you with a clinician, while the drug is compounded by one of two kinds of facility.
- 503A pharmacy: a compounding pharmacy licensed and overseen mainly by its state board of pharmacy, which generally compounds for individual patients based on prescriptions.
- 503B outsourcing facility: a facility that registers with FDA and is held to federal manufacturing quality standards.
Registration is not approval. FDA says registering as a 503B outsourcing facility does not amount to FDA approval or licensure of the facility or its products. 503A pharmacies and 503B facilities do not go through FDA premarket review of their compounded drugs. The law also creates no "FDA-approved" or "FDA-licensed" pharmacy designation (FDA warning letter, June 8, 2026).
In that letter, FDA suggested the company identify the entities that produce the compounded products on its website. You can ask any provider the same thing: who compounds this, and is it a 503A pharmacy or a 503B facility? For how oversight differs between the two, see 503A vs 503B: oversight, quality and what to ask.
What a trustworthy GLP-1 page should disclose
A trustworthy page tells you what the product is, who makes it, who decides whether it suits you, and what could rule you out. It says this in plain words near the product, not in a footer.
- Compounded status: the product is compounded and not FDA-approved.
- Who makes it: a state-licensed 503A pharmacy or a 503B outsourcing facility. The facility should not be presented with an "FDA-approved" or "FDA-licensed" badge.
- Clinician review: a licensed clinician reviews your intake and prescribes only if appropriate. Not everyone qualifies.
- Safety screening: the Wegovy (semaglutide) label says Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), a rare thyroid cancer, or with multiple endocrine neoplasia syndrome type 2 (MEN 2), an inherited condition that causes tumors in hormone glands. It also warns about acute pancreatitis (Wegovy label, DailyMed). People with a history of pancreatitis should not use these medications either, and a licensed clinician screens for all of this.
- Availability: which states are served, any delivery limits, and where to find current pricing.
- Honest evidence: research described as research, with sources, and no promised amounts or timelines.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
The semaglutide and tirzepatide pathways use compounded medications, which are not FDA-approved. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities, and FDA registration is not FDA approval or licensure.
- You complete a structured online intake.
- An independent licensed clinician reviews it, including screening for MTC, MEN 2 and pancreatitis history. Some treatments or states may require a live visit.
- If prescribed, a licensed partner pharmacy ships the medication directly to you. Use follows your clinician's guidance and pharmacy instructions.
Eligibility depends on your intake and clinical review, and that's how it should work. New Blue is LegitScript certified. Availability varies by state, so check state availability. Semaglutide and tirzepatide can't ship to every state we serve. Our compounding disclosure explains how compounding works, and current pricing is on the Semaglutide GLP-1 pathway and Tirzepatide GLP-1 pathway pages.
Frequently Asked Questions
Are compounded GLP-1s illegal after the FDA warning letters?
The warning letters did not ban compounded GLP-1s. They were notices about false or misleading marketing that asked companies to correct violations. Compounded drugs must still meet section 503A or 503B conditions. FDA says they should only be used when an FDA-approved drug is not able to meet a patient's medical needs.
How does compounded semaglutide differ from Ozempic?
FDA says a compounded drug should not be described as a generic version of, or the same as, an FDA-approved drug. Ozempic and Wegovy are FDA-approved brand products, and compounded semaglutide shares the active ingredient but is not the same product. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold.
Is there such a thing as an FDA-approved pharmacy?
No. FDA does not approve or license any pharmacy or outsourcing facility, and federal law creates no such designation. A 503B outsourcing facility registers with FDA, but registration is not approval of the facility or its products.
Who makes compounded semaglutide or tirzepatide?
A state-licensed 503A compounding pharmacy or a 503B outsourcing facility makes it. A telehealth company is usually a platform, not the compounder. A trustworthy provider will tell you which type of facility prepares your medication.
Should I stop my compounded GLP-1 because of the warning letters?
Talk with your clinician before making any change. The letters focused on how companies marketed compounded drugs, not on any individual patient's treatment. You can also run the marketing checklist in this article on your provider's website and ask who compounds your medication.
How can I find out if a telehealth company received a warning letter?
FDA publishes warning letters on FDA.gov, and you can search its warning letter database by company name. A letter shows what FDA found at a point in time and what it asked the company to fix. It does not tell you whether the company has since corrected the problems.
Sources
- FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. U.S. Food and Drug Administration, 2026.
- Warning Letter MARCS-CMS 728274 (telehealth company), June 8, 2026. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2026.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026.
- WEGOVY (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine (FDA label), 2025.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Decisions about whether any treatment is appropriate for you are made by an independent licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.